As we approach 2020, I want to reflect on what we have achieved at Aiforia so far and thank our amazing customers and partners for collaborating with us throughout the year.
Nearly two years after launching the state-of-the-art deep learning AI-driven Aiforia Platform, we have successfully created and deployed over 200 AI models for more than 30 different diseases — such as breast cancer, neurodegenerative diseases like Parkinson’s disease, liver diseases like nonalcoholic steatohepatitis (NASH), lung diseases, and more.
During the past year, the Aiforia team also grew with 10 new hires across Finland, the US, and recently the Netherlands. Our scientists and in-house AI experts have been working tirelessly to provide novel AI solutions for our customers. Our most recent software release of high-speed image analysis tools and features, Velocity, is one we are particularly proud of. Velocity includes the first-in-class active learning tool, Annotation Assistant, which significantly speeds up the time it takes to train your AI models.
At Aiforia we aim to improve healthcare from discovery to treatment, by providing solutions for medical research, preclinical analysis in drug development, and clinical diagnostics. I would therefore like to thank all of our customers and collaborators across these areas and industries. We at Aiforia feel privileged and grateful to work with such world-leading scientific and medical experts, institutions, and organizations. At Aiforia we are also scientists — curious and driven to continually make new discoveries to improve our understanding of diseases and their treatments and we are grateful to work together with you on our joint mission.
Looking ahead at 2020, we are particularly excited to start working with more clinical customers as Aiforia recently took its first significant steps into diagnostics. Our CE-IVD marked Aiforia Clinical product is now available and we won a €2.1M EU grant to help us move towards validating specific AI models to help diagnose some of the most common cancer types in the world, including prostate and lung cancer.
AI is becoming more and more ubiquitous in medicine and scientific research, we are therefore looking forward to it holding a place of permanency in image-based diagnostics and for greater adoption worldwide. With this AI expansion, Aiforia’s vision is to democratize diagnostics and healthcare globally. Thank you for working with us to advance our vision!
Happy holidays and we wish you a successful 2020!
2019 in numbers